The Small Molecule Analytical Development and Pharmaceutical Sciences departments perform quality tests on new pharmaceutical drugs, test the release of active ingredients, verify the stability of new medicines, and develop optimal ways of administering the medication. As such, the departments are of crucial importance to the support of Janssen Supply Chain (JSC) and a focal point of its Global Public Health organization.
Stef Heylen, Managing Director of Janssen, is excited: “The fact that Johnson & Johnson is giving Janssen the green light to invest this heavily in Beerse highlights the importance of our Flanders-based company.
Both the R&D- and production departments will benefit from this. It’s definitely a major step in prepping our campus for the future, and also strengthens the positon of our production departments.”
Centralization creates more synergy
Construction started in 2016, and the 10,400-m2 building will be operational in 2020. No fewer than 250 scientists, laboratory workers, management staff and supporting employees will work there. They are currently still divided over several sections across the campus, but will be centralized for activities pertaining to the development of existing and new medicines in what will be a state-of-the-art laboratory.